223677-03-0

Upstream product

• 23676-09-7 ethyl 4-ethoxybenzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 75-07-0 acetaldehyde 
• 676560-15-9 Ethyl (cis/trans)-4-<(tert-butyldimethylsilyl)oxy>cyclohexanecarboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 

Downstream Products

• 213914-44-4 Thioacetic acid S-{4-ethoxy-1-[(S)-2-(4-fluoro-phenyl)-1-phenylcarbamoyl-ethylcarbamoyl]-cyclohexylmethyl} ester 
• 213914-37-5 Thioacetic acid S-{4-ethoxy-1-[(S)-2-(4-hydroxy-phenyl)-1-phenylcarbamoyl-ethylcarbamoyl]-cyclohexylmethyl} ester 
• 223677-17-6 4-Ethoxy-1-hydroxymethyl-cyclohexanecarboxylic acid ((S)-1-cyclohexylcarbamoyl-2-phenyl-ethyl)-amide 
• 223677-38-1 4-Ethoxy-1-hydroxymethyl-cyclohexanecarboxylic acid [(S)-2-(4-ethoxy-phenyl)-1-phenylcarbamoyl-ethyl]-amide 
• 223677-34-7 4-Ethoxy-1-hydroxymethyl-cyclohexanecarboxylic acid [(S)-2-(4-hydroxy-phenyl)-1-phenylcarbamoyl-ethyl]-amide 

Relevant academic research and scientific papers

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula (I) or a salt thereof are provided, wherein X1, X2, X3, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of Formula (I) and salts and solvates are provided; wherein R, R5, R6 and Q are defined as in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Design and synthesis of thiol containing inhibitors of matrix metalloproteinases

A series of thiol containing derivatives was prepared. Several of these compounds were found to inhibit matrix metalloproteinases 1, 3, and 9 with selectivity towards 3 and 9. Compounds 15, 20 and 22 were administered to rats orally at 75 μmol/kg. Drug levels of compounds 20 and 22 in the plasma were found to exceed the IC50 values for MMP 3 and 9 four hours after administration.